Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 31,000 | |||
5 mg | 在庫あり | ¥ 66,500 | |||
10 mg | 在庫あり | ¥ 104,500 | |||
25 mg | 在庫あり | ¥ 173,000 | |||
50 mg | 在庫あり | ¥ 243,500 | |||
100 mg | 在庫あり | ¥ 328,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 73,000 |
説明 | Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. |
In vitro | Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways. |
別名 | CBT-101, PLB-1001 |
分子量 | 424.38 |
分子式 | C20H15F3N8 |
CAS No. | 1440964-89-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (110.74 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bozitinib 1440964-89-5 Tyrosine Kinase/Adaptors c-Met/HGFR CBT-101 PLB1001 Vebreltinib CBT 101 inhibit PLB-1001 CBT101 PLB 1001 Inhibitor inhibitor